INTRODUCTION: The RNASEL and HPC2/ELAC2 genes have been implicated in hereditary prostate cancer. Further assessment of the role of these genes in sporadic prostate cancer in African American men (AAM) is warranted. METHODS: Genotyping of HPC2/ELAC2 variants (S217L, A541T), along with RNASEL variants (R462Q and E541D) was completed in 155 African American sporadic and 88 familial prostate cancer cases, and 296 healthy male controls. Logistic regression analysis was performed and odds ratios (OR) were calculated, while correcting for both age and population stratification using admixture informative markers. RESULTS: The HPC2/ELAC2 217L allele was significantly associated with risk of prostate cancer when taking all cases into account (OR = 1.6; 1.0-2.6; P = 0.03). The RNASEL 541D allele was associated with a decrease in risk of prostate cancer in sporadic cases (OR = 0.4; 0.2-0.8; P = 0.01). We did not detect an association between prostate cancer risk and the RNASEL R462Q variant. Results from haplotype analyses of the two RNASEL variants revealed highly significant differences in haplotype allele frequencies between cases and controls suggesting a synergistic effect at the RNASEL locus. One haplotype in particular (462R-541D) is far more frequent in our control population and shows a strong protective effect against prostate cancer (OR = 0.47, P = 8.1 x 10(-9)). CONCLUSIONS: These results suggest that HPC2/ELAC2 and RNASEL may play a role, however minor, in prostate cancer risk among AAM.
INTRODUCTION: The RNASEL and HPC2/ELAC2 genes have been implicated in hereditary prostate cancer. Further assessment of the role of these genes in sporadic prostate cancer in African American men (AAM) is warranted. METHODS: Genotyping of HPC2/ELAC2 variants (S217L, A541T), along with RNASEL variants (R462Q and E541D) was completed in 155 African American sporadic and 88 familial prostate cancer cases, and 296 healthy male controls. Logistic regression analysis was performed and odds ratios (OR) were calculated, while correcting for both age and population stratification using admixture informative markers. RESULTS: The HPC2/ELAC2 217L allele was significantly associated with risk of prostate cancer when taking all cases into account (OR = 1.6; 1.0-2.6; P = 0.03). The RNASEL 541D allele was associated with a decrease in risk of prostate cancer in sporadic cases (OR = 0.4; 0.2-0.8; P = 0.01). We did not detect an association between prostate cancer risk and the RNASELR462Q variant. Results from haplotype analyses of the two RNASEL variants revealed highly significant differences in haplotype allele frequencies between cases and controls suggesting a synergistic effect at the RNASEL locus. One haplotype in particular (462R-541D) is far more frequent in our control population and shows a strong protective effect against prostate cancer (OR = 0.47, P = 8.1 x 10(-9)). CONCLUSIONS: These results suggest that HPC2/ELAC2 and RNASEL may play a role, however minor, in prostate cancer risk among AAM.
Authors: R A Kittles; A B Baffoe-Bonnie; T Y Moses; C M Robbins; C Ahaghotu; P Huusko; C Pettaway; S Vijayakumar; J Bennett; G Hoke; T Mason; S Weinrich; J M Trent; F S Collins; S Mousses; J Bailey-Wilson; P Furbert-Harris; G Dunston; I J Powell; J D Carpten Journal: J Med Genet Date: 2005-09-09 Impact factor: 6.318
Authors: Nicola J Camp; Jeff Swensen; Benjamin D Horne; James M Farnham; Alun Thomas; Lisa A Cannon-Albright; Sean V Tavtigian Journal: Genet Epidemiol Date: 2005-04 Impact factor: 2.135
Authors: Sarah E Daugherty; Richard B Hayes; Meredith Yeager; Gerald L Andriole; Nilanjan Chatterjee; Wen-Yi Huang; William B Isaacs; Elizabeth A Platz Journal: Prostate Date: 2007-06-01 Impact factor: 4.104
Authors: Fredrik Wiklund; Björn-Anders Jonsson; Anthony J Brookes; Linda Strömqvist; Jan Adolfsson; Monica Emanuelsson; Hans-Olov Adami; Katarina Augustsson-Bälter; Henrik Grönberg Journal: Clin Cancer Res Date: 2004-11-01 Impact factor: 12.531
Authors: Anatoly Urisman; Ross J Molinaro; Nicole Fischer; Sarah J Plummer; Graham Casey; Eric A Klein; Krishnamurthy Malathi; Cristina Magi-Galluzzi; Raymond R Tubbs; Don Ganem; Robert H Silverman; Joseph L DeRisi Journal: PLoS Pathog Date: 2006-03-31 Impact factor: 6.823
Authors: L J Ricks-Santi; V Apprey; T Mason; B Wilson; M Abbas; W Hernandez; S Hooker; M Doura; G Bonney; G Dunston; R Kittles; C Ahaghotu Journal: Prostate Cancer Prostatic Dis Date: 2012-07-17 Impact factor: 5.554
Authors: Mara S Meyer; Kathryn L Penney; Jennifer R Stark; Fredrick R Schumacher; Howard D Sesso; Massimo Loda; Michelangelo Fiorentino; Stephen Finn; Richard J Flavin; Tobias Kurth; Alkes L Price; Edward L Giovannucci; Katja Fall; Meir J Stampfer; Jing Ma; Lorelei A Mucci Journal: Carcinogenesis Date: 2010-06-24 Impact factor: 4.944
Authors: Jonathan D Schoenfeld; Danielle N Margalit; Julie L Kasperzyk; Irene M Shui; Jennifer R Rider; Mara M Epstein; Allison Meisner; Stacey A Kenfield; Neil E Martin; Paul L Nguyen; Philip W Kantoff; Edward L Giovannucci; Meir J Stampfer; Lorelei A Mucci Journal: Clin Cancer Res Date: 2013-02-04 Impact factor: 12.531
Authors: Joke Beuten; Jonathan A L Gelfond; Jennifer L Franke; Stacey Shook; Teresa L Johnson-Pais; Ian M Thompson; Robin J Leach Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-01-19 Impact factor: 4.254